LDLR-targeted orlistat therapeutic nanoparticles: Peptide selection, assembly, characterization, and cell-uptake in breast cancer cell lines
LDLR-OTNs demonstrated receptor-mediated uptake and potent cytotoxicity in LDLR- and FAS- overexpressing breast cancer cells. These findings support LDLR-targeted nanoparticles as a promising approach for delivering FAS inhibitors to LDLR-rich tumours, meriting further investigation in targeted cancer therapy development.
Authors
- David Needham (ORCID: https://orcid.org/0000-0002-0082-9148)
- George Bebawy (ORCID: https://orcid.org/0000-0001-7841-7218)
- Philip M. Williams (ORCID: https://orcid.org/0000-0002-1822-2133)
- J. Burley (ORCID: https://orcid.org/0000-0003-4030-1484)
- Pamela Collier
Institutions
- University of Nottingham (GB)
- Alexandria University (EG)
Publication Details
- Journal
- International Journal of Pharmaceutics
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.ijpharm.2025.125574
- Citations
- 5
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 4.68
Funders
- Egyptian Cultural and Educational Bureau